Crisprtx CRISPR Therapeutics develops gene-editing therapies across hemoglobinopathies, oncology, autoimmune disease, cardiovascular disease, and regenerative medicine. Its CASGEVY therapy is approved in some countries for eligible patients with sickle cell disease or transfusion-dependent beta thalassemia.